Rachid Izzar Biography and Net Worth

Insider of Biogen

Rachid Izzar is Executive Vice President, Global Product Strategy & Commercialization, and has served on the Executive Committee since July 2021. Mr. Izzar joined Biogen in October 2019 as President of the Intercontinental Region, including Latin America, Australia, Asia, Japan, the Middle East, Africa, Turkey, and Russia, and the Biosimilars business unit. Before joining Biogen, he was a Country President for AstraZeneca in France. He held several leadership roles at AstraZeneca, including responsibility for all business and commercial operations, as well as the build-out and management of the global cardiovascular franchise. Before that, he was based in Shanghai and served as Vice President of Strategic Transformation, led the China portfolio, and served as Vice President of Commercial International covering China, Australia, Brazil, Russia, Latin America, Asia, Turkey, the Middle East, and Africa.

Mr. Izzar holds an M.B.A. from the University of Sherbrooke in Canada and a graduate diploma in Business Transformation from Harvard University.

What is Rachid Izzar's net worth?: The estimated net worth of Rachid Izzar is at least $1.15 million as of July 8th, 2025. Izzar owns 6,330 shares of Biogen stock worth more than $1,151,933 as of December 5th. This net worth evaluation does not reflect any other assets that Izzar may own. Additionally, Izzar receives a salary of $1,270,000.00 as Insider at Biogen. Learn More about Rachid Izzar's net worth.
How old is Rachid Izzar?: Izzar is currently 49 years old. There are 7 older executives and no younger executives at Biogen. The oldest executive at Biogen is Ms. Susan H. Alexander Esq., Executive VP & Chief Legal Officer, who is 67 years old. Learn More on Rachid Izzar's age.
What is Rachid Izzar's salary?: As the Insider of Biogen Inc., Izzar earns $1,270,000.00 per year. There are 5 executives that earn more than Izzar. The highest earning executive at Biogen is Mr. Christopher A. Viehbacher, President, CEO & Director, who commands a salary of $4,070,000.00 per year. Learn More on Rachid Izzar's salary.
How do I contact Rachid Izzar?: The corporate mailing address for Izzar and other Biogen executives is 225 BINNEY STREET, CAMBRIDGE MA, 02142. Biogen can also be reached via phone at (617) 679-2000 and via email at [email protected]. Learn More on Rachid Izzar's contact information.
Has Rachid Izzar been buying or selling shares of Biogen?: Rachid Izzar has not been actively trading shares of Biogen in the last ninety days. Most recently, Rachid Izzar sold 2,223 shares of the business's stock in a transaction on Tuesday, July 8th. The shares were sold at an average price of $135.00, for a transaction totalling $300,105.00. Following the completion of the sale, the insider now directly owns 6,330 shares of the company's stock, valued at $854,550. Learn More on Rachid Izzar's trading history.
Who are Biogen's active insiders?: Biogen's insider roster includes Susan Alexander (EVP), Rachid Izzar (Insider), Brian Posner (Director), Eric Rowinsky (Director), Alfred Sandrock (insider), Stephen Sherwin (Director), Stephen Sherwin (Director), Stephen Sherwin (Director), Priya Singhal (Insider), and Michel Vounatsos (CEO). Learn More on Biogen's active insiders.
Are insiders buying or selling shares of Biogen?: During the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 11,500 shares worth more than $1,683,325.55. The most recent insider tranaction occured on September, 2nd when insider Priya Singhal sold 517 shares worth more than $69,045.35. Insiders at Biogen own 0.2% of the company. Learn More about insider trades at Biogen.
Information on this page was last updated on 9/2/2025.

Rachid Izzar Insider Trading History at Biogen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/8/2025	Sell	2,223	$135.00	$300,105.00	6,330

Rachid Izzar Buying and Selling Activity at Biogen

Biogen Company Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $181.98

$179.27

$182.69

50 Day Range

MA: $157.91

$137.37

$181.98

2 Week Range

Now: $181.98

$110.04

$185.17

Volume

1,233,937 shs

Average Volume

1,905,301 shs

Market Capitalization

$26.70 billion

P/E Ratio

16.59

Dividend Yield

N/A

Beta

0.13

Rachid Izzar Biography and Net Worth

What is Rachid Izzar's net worth?

How old is Rachid Izzar?

What is Rachid Izzar's salary?

How do I contact Rachid Izzar?

Has Rachid Izzar been buying or selling shares of Biogen?

Who are Biogen's active insiders?

Are insiders buying or selling shares of Biogen?